Статті в журналах з теми "Ozanimod"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Ozanimod".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Daykin, Nicola. "Ozanimod for relapsing remitting multiple sclerosis and how Brexit changed the journey." Journal of Prescribing Practice 4, no. 2 (February 2, 2022): 64–71. http://dx.doi.org/10.12968/jprp.2022.4.2.64.
Повний текст джерелаHarris, Sarah, Jonathan Q. Tran, Harry Southworth, Collin M. Spencer, Bruce A. C. Cree, and Scott S. Zamvil. "Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS." Neurology - Neuroimmunology Neuroinflammation 7, no. 5 (July 31, 2020): e839. http://dx.doi.org/10.1212/nxi.0000000000000839.
Повний текст джерелаCohen, Jeffrey A., Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof W. Selmaj, Lawrence Steinman, Eva K. Havrdová, et al. "Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study." Multiple Sclerosis Journal 25, no. 9 (July 25, 2018): 1255–62. http://dx.doi.org/10.1177/1352458518789884.
Повний текст джерелаPanaccione, R., S. Danese, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, A. Afzali, and M. T. Abreu. "P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i591—i593. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0594.
Повний текст джерелаSandborn, William, Brian Feagan, Douglas Wolf, Geert D’Haens, Séverine Vermeire, Stephen Hanauer, Subrata Ghosh, Harry Southworth, and Sarah Harris. "EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS." Inflammatory Bowel Diseases 27, Supplement_1 (January 1, 2021): S6. http://dx.doi.org/10.1093/ibd/izaa347.014.
Повний текст джерелаArmuzzi, A., R. K. Cross, G. Lichtenstein, J. Calkwood, A. Pai, M. Pondel, H. A. Ahmad, et al. "DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i094—i095. http://dx.doi.org/10.1093/ecco-jcc/jjab232.084.
Повний текст джерелаSiegmund, B., J. Axelrad, M. Pondel, M. T. Osterman, H. A. Ahmad, A. Memaj, M. Regueiro, A. Armuzzi, and A. Afzali. "DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i092—i093. http://dx.doi.org/10.1093/ecco-jcc/jjab232.082.
Повний текст джерелаDubinsky, M. C., U. Mahadevan, L. Charles, S. Afsari, A. Henry, G. Comi, K. Selmaj, and C. J. van der Woude. "DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S088—S089. http://dx.doi.org/10.1093/ecco-jcc/jjab073.092.
Повний текст джерелаShen, J., D. Tatosian, L. Sid-Otmane, N. Teuscher, L. Chen, P. Zhang, G. S. Tirucherai, D. Chitakara, and C. Marta. "P332 Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S355—S357. http://dx.doi.org/10.1093/ecco-jcc/jjab076.456.
Повний текст джерелаShen, Jun, Daniel Tatosian, Lamia Sid-Otmane, Nathan Teuscher, Lu Chen, Peijin Zhang, Giridhar Tirucherai, Denesh Chitkara, and Cecilia Marta. "POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS." Inflammatory Bowel Diseases 28, Supplement_1 (January 22, 2022): S17—S18. http://dx.doi.org/10.1093/ibd/izac015.025.
Повний текст джерелаSwallow, Elyse, Oscar Patterson-Lomba, Lei Yin, Rina Mehta, Corey Pelletier, David Kao, James K. Sheffield, Tim Stonehouse, and James Signorovitch. "Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis." Journal of Comparative Effectiveness Research 9, no. 4 (March 2020): 275–85. http://dx.doi.org/10.2217/cer-2019-0169.
Повний текст джерелаBonek, Robert. "Ozanimod w terapii rzutowo-remisyjnej postaci stwardnienia rozsianego – opisy przypadków." Medycyna Faktów 15, no. 2 (55) (June 20, 2022): 236–39. http://dx.doi.org/10.24292/01.mf.0222.18.
Повний текст джерелаPanaccione, R., S. Danese, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, L. Charles, A. Afzali, and M. T. Abreu. "P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i534—i535. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0535.
Повний текст джерелаSands, B. E., A. Dignass, P. Irving, M. Chiorean, M. Long, D. Eren, H. A. Ahmad, et al. "P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i339—i340. http://dx.doi.org/10.1093/ecco-jcc/jjab232.443.
Повний текст джерелаDignass, A., M. Regueiro, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, S. Vermeire, and D. T. Rubin. "P687 Durability of recaptured response to ozanimod during the True North open-label extension." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i817—i818. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0817.
Повний текст джерелаDanese, S., M. T. Abreu, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, L. Charles, R. Panaccione, and A. Afzali. "DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i101—i102. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0077.
Повний текст джерелаVermeire, S., J. F. Colombel, M. V. Chiorean, S. Ghosh, A. Jain, G. Lawlor, M. T. Osterman, H. Wu, J. B. Canavan, and D. T. Rubin. "P773 Extended induction in the True North open-label extension study: clinical outcomes of ~2 years of ozanimod treatment." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i903—i904. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0903.
Повний текст джерелаLamb, Yvette N. "Ozanimod: First Approval." Drugs 80, no. 8 (May 8, 2020): 841–48. http://dx.doi.org/10.1007/s40265-020-01319-7.
Повний текст джерелаFloden, L., T. P. Pham, J. Kumar, B. Becker, J. W. Shaw, and T. Tencer. "P468 Evaluation of work productivity and activity impairment in moderate-to-severe ulcerative colitis participants treated with ozanimod in the phase 3 True North study." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i441—i442. http://dx.doi.org/10.1093/ecco-jcc/jjab232.595.
Повний текст джерелаReinisch, W., J. Axelrad, H. A. Ahmad, M. Pondel, S. Ather, A. Elegbe, C. Sninsky, and R. Longman. "P431 Early mucosal healing at week, 10 with ozanimod predicts clinical outcomes at week, 52: Post hoc analysis of the phase, 3 True North clinical trial." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i415. http://dx.doi.org/10.1093/ecco-jcc/jjab232.558.
Повний текст джерелаDanese, S., M. T. Abreu, A. Afzali, J. B. Canavan, A. Jain, H. Wu, A. Petersen, R. Panaccione, and D. C. Wolf. "P719 Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatment." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i848—i850. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0849.
Повний текст джерелаVermeire, S., J. F. Colombel, D. T. Rubin, S. Ghosh, A. Jain, G. Lawlor, M. T. Osterman, H. Wu, J. B. Canavan, and M. V. Chiorean. "P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i844—i845. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0845.
Повний текст джерелаCohen, Nathaniel, Tenzin Choden, David Choi, Noa Cleveland, Russell Cohen, Sushila Dalal, Atsushi Sakuraba, Ira Hanan, and David Rubin. "REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER." Inflammatory Bowel Diseases 28, Supplement_1 (January 22, 2022): S109. http://dx.doi.org/10.1093/ibd/izac015.175.
Повний текст джерелаWendt, Trevor S., Yu Jing Li, and Rayna J. Gonzales. "Ozanimod, an S1PR1 ligand, attenuates hypoxia plus glucose deprivation-induced autophagic flux and phenotypic switching in human brain VSM cells." American Journal of Physiology-Cell Physiology 320, no. 6 (June 1, 2021): C1055—C1073. http://dx.doi.org/10.1152/ajpcell.00044.2021.
Повний текст джерелаUngaro, R., C. A. Siegel, B. A. C. Cree, K. W. Selmaj, H. A. Ahmad, A. Pai, S. Ather, et al. "P486 Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i452. http://dx.doi.org/10.1093/ecco-jcc/jjab232.613.
Повний текст джерелаVermeire, S., A. Dignass, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, D. T. Rubin, and M. Regueiro. "DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i103—i104. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0079.
Повний текст джерелаKuczynski, Andrea M., and Jiwon Oh. "Ozanimod for the treatment of relapsing forms of multiple sclerosis." Neurodegenerative Disease Management 11, no. 3 (June 2021): 207–20. http://dx.doi.org/10.2217/nmt-2021-0005.
Повний текст джерелаBrockmeier, Bernd. ""Geringer Zusatznutzen" für Ozanimod." NeuroTransmitter 32, no. 5 (May 2021): 16–17. http://dx.doi.org/10.1007/s15016-021-9149-y.
Повний текст джерелаKathmann, Wiebke. "Ozanimod als neue Behandlungsoption." Gastro-News 9, no. 2 (April 2022): 60. http://dx.doi.org/10.1007/s15036-022-2493-3.
Повний текст джерелаHof, Teresa, and Peter Hasselblatt. "Ozanimod bei Colitis ulcerosa." Gastro-News 8, no. 6 (December 2021): 28–29. http://dx.doi.org/10.1007/s15036-021-2431-9.
Повний текст джерелаCiftci-Kavaklioglu, Beyza, and E. Ann Yeh. "Ozanimod in Multiple Sclerosis." European Neurological Review 14, no. 2 (2019): 73. http://dx.doi.org/10.17925/enr.2019.14.2.73.
Повний текст джерелаMohamed, Rana, Cody Kern, Aaron Fein, Terrence Barrett, and Courtney Perry. "SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD." Inflammatory Bowel Diseases 28, Supplement_1 (January 22, 2022): S110—S111. http://dx.doi.org/10.1093/ibd/izac015.177.
Повний текст джерелаLassiter, Grace, Carlie Melancon, Tyler Rooney, Anne-Marie Murat, Jessica S. Kaye, Adam M. Kaye, Rachel J. Kaye, et al. "Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects." Neurology International 12, no. 3 (December 3, 2020): 89–108. http://dx.doi.org/10.3390/neurolint12030016.
Повний текст джерелаCaldera, F., R. Maddux, R. Ungaro, A. Kaur, E. Brown, S. Hu, J. K. Sheffield, D. Silva, S. Harris, and B. A. C. Cree. "P516 Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i643—i644. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0646.
Повний текст джерелаDignass, A., M. Regueiro, J. F. Colombel, A. Jain, J. B. Canavan, H. Wu, G. Lawlor, M. T. Osterman, S. Vermeire, and D. T. Rubin. "DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i110—i111. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0083.
Повний текст джерелаTatosian, D., J. Shen, L. Chen, J. Lavigne, N. Teuscher, S. Harris, D. Chitkara, G. S. Tirucherai, and C. Marta. "P315 Population pharmacokinetics and pharmacodynamics of ozanimod in ulcerative colitis." Journal of Crohn's and Colitis 15, Supplement_1 (May 1, 2021): S341—S342. http://dx.doi.org/10.1093/ecco-jcc/jjab076.439.
Повний текст джерелаTatosian, Daniel, Jun Shen, Lu Chen, Jean Lavigne, Nathan Teuscher, Sarah Harris, Denesh Chitkara, Giridhar Tirucherai, and Cecilia Marta. "POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OZANIMOD IN ULCERATIVE COLITIS." Inflammatory Bowel Diseases 28, Supplement_1 (January 22, 2022): S16. http://dx.doi.org/10.1093/ibd/izac015.024.
Повний текст джерелаGroh, Jan. "Ozanimod senkt Schubrate bei RRMS." InFo Neurologie + Psychiatrie 22, no. 11 (November 2020): 50. http://dx.doi.org/10.1007/s15005-020-1519-7.
Повний текст джерелаAlaskar, Dimah, Zainab AlMusa, and Turki AlAmeel. "Letter: Ozanimod and latent tuberculosis." Alimentary Pharmacology & Therapeutics 57, no. 3 (January 15, 2023): 353–54. http://dx.doi.org/10.1111/apt.17311.
Повний текст джерелаDanese, S., J. F. Colombel, T. Ponich, I. Jovanovic, P. Bossuyt, R. Longman, O. Alekseeva, et al. "DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i093—i094. http://dx.doi.org/10.1093/ecco-jcc/jjab232.083.
Повний текст джерелаSiegmund, B., G. Y. Melmed, P. M. Irving, A. Pai, A. Patel, J. K. Sheffield, F. Caldera, B. A. C. Cree, and M. C. Dubinsky. "P402 Incidence and outcomes of herpes zoster in the ozanimod phase, 3 ulcerative colitis and relapsing multiple sclerosis clinical program." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i395—i396. http://dx.doi.org/10.1093/ecco-jcc/jjab232.529.
Повний текст джерелаCohen, N. A., D. Choi, N. Garcia, N. Choi, E. Picker, N. Krugliak-Cleveland, R. Cohen, et al. "P562 Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary center." Journal of Crohn's and Colitis 17, Supplement_1 (January 30, 2023): i692—i693. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0692.
Повний текст джерелаSandborn, William J., Brian G. Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J. Liu, AnnKatrin Petersen, et al. "Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study." Journal of Crohn's and Colitis 15, no. 7 (January 13, 2021): 1120–29. http://dx.doi.org/10.1093/ecco-jcc/jjab012.
Повний текст джерелаAntonelli, E., R. Del Sordo, O. Morelli, V. Villanacci, and G. Bassotti. "Update on ozanimod for ulcerative colitis." Drugs of Today 58, no. 7 (2022): 351. http://dx.doi.org/10.1358/dot.2022.58.7.3408818.
Повний текст джерелаEiden, Petra. "Frühe Reduktion der Läsionslast unter Ozanimod." InFo Neurologie + Psychiatrie 23, no. 7-8 (August 2021): 53. http://dx.doi.org/10.1007/s15005-021-2037-y.
Повний текст джерелаRay, Katrina. "Ozanimod is efficacious in ulcerative colitis." Nature Reviews Gastroenterology & Hepatology 18, no. 11 (October 1, 2021): 748. http://dx.doi.org/10.1038/s41575-021-00532-3.
Повний текст джерелаAnja, Borchers. "MS-Therapie: Aktuelle Daten zu Ozanimod." Nervenheilkunde 37, no. 03 (February 2018): 216. http://dx.doi.org/10.1055/s-0038-1638278.
Повний текст джерелаOttenjann, Henrike. ""Hit smart and early" mit Ozanimod." InFo Neurologie + Psychiatrie 25, no. 2 (February 2023): 53. http://dx.doi.org/10.1007/s15005-023-3181-3.
Повний текст джерелаSamjoo, Imtiaz A., Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A. Häring, Dee Stoneman, Luisa Klotz, and Nicholas Adlard. "Efficacy classification of modern therapies in multiple sclerosis." Journal of Comparative Effectiveness Research 10, no. 6 (April 2021): 495–507. http://dx.doi.org/10.2217/cer-2020-0267.
Повний текст джерелаPotì, Francesco, Carmine Giorgio, Irene Zini, Jerzy-Roch Nofer, Valentina Vivo, Simone Palese, Vigilio Ballabeni, Elisabetta Barocelli, and Simona Bertoni. "Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury." Pharmaceuticals 13, no. 10 (October 9, 2020): 298. http://dx.doi.org/10.3390/ph13100298.
Повний текст джерела